title: Lipoxygenase pathway receptor expression in ovarian cancer.
abstract: OBJECTIVE
  To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy.
  
  
  METHODS
  Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2).
  
  
  RESULTS
  245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival.
  
  
  CONCLUSIONS
  LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.
authors.affiliation: Department of Obstetrics and Gynecology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36607, USA. rocconi@usouthal.edu
authors.forename: Rodney P
authors.initials: RP
authors.lastname: Rocconi
authors.forename: Tyler O
authors.initials: TO
authors.lastname: Kirby
authors.forename: Robert S
authors.initials: RS
authors.lastname: Seitz
authors.forename: Rod
authors.initials: R
authors.lastname: Beck
authors.forename: J Michael
authors.initials: JM
authors.lastname: Straughn
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001094:Arachidonate 5-Lipoxygenase / Q000032:analysis*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D017671:Platinum Compounds / Q000627:therapeutic use; D018102:Receptors, Leukotriene B4 / Q000032:analysis*; D015398:Signal Transduction; D046888:Tissue Array Analysis
chemical_list: D000970:Antineoplastic Agents; C513240:LTB4R protein, human; C485878:LTB4R2 protein, human; D016859:Lipoxygenase Inhibitors; D017671:Platinum Compounds; D018102:Receptors, Leukotriene B4; D001094:Arachidonate 5-Lipoxygenase